Meta-Analysis of miRNA Expression and Diagnostic Value in Human Glioma

Abstract

Background: The diagnostic value of microRNA in glioma was comprehensively evaluated by meta-analysis. Methods: PubMed, Embase, The Cochrane Library, China biology medicine, China national knowledge infrastructure, Wanfang database, and Chinese Weipu database were searched by computer from inception to June 2022. Meta-analysis was performed with Meta-Disc 1.4 (Hospital Univeritario Ramón y Cajal, Madrid, Spain) software and Stata 12.0 (StataCorp LLC, College Station, TX, USA, http://www.stata.com/) software to calculate the pooled sensitivity, pooled specificity, pooled positive likelihood ratio, pooled negative likelihood ratio, and pooled diagnostic odds ratio (DOR). The presence of publication bias was assessed using Deeks funnel plot asymmetry test. Subgroup analysis was performed according to the sample type and the region of the included population. Fagans nomogram was used to evaluate the pre- and post-probabilities of positive likelihood ratio (PLR) and negative likelihood ratio (NLR) after microRNA application. Results: Finally, 9 literature were included, including 455 patients with glioma and 342 controls. The heterogeneity test showed that there was obvious heterogeneity caused by non threshold effect. Meta-analysis showed that pooled SEN was 0.74 (95% CI (confidence intervals): 0.70, 0.78), pooled SPE (specificity) was 0.81 (95% CI: 076, 0.85), pooled PLR was 4.53 (95% CI: 3.81, 5.38), pooled NLR was 0.26 (95% CI: 0.23, 0.30), pooled DOR was 20.53 (95% CI: 9.09, 40.53). The SROC (summary ROC) curve shows area under the curve (AUC) was 0.8935. The asymmetric test of deeks funnel chart suggests that there is no significant publication bias. Conclusion the expression level of microRNA has a certain value in the diagnosis of glioma. Conclusions: MicroRNA expression level has a certain value for the diagnosis of glioma.